Tag: MSI

Short tandem repeat mutations regulate gene expression in colorectal cancer

A novel STR panel for human protein-coding genes To explore STR mutations in CRC, we first annotated STRs in the introns, exons, and promoter sequence of all protein-coding genes in the GRCh38 reference genome (“Methods”). We discarded STR loci for which genotyping was expected to be inaccurate due to genomic…

Continue Reading Short tandem repeat mutations regulate gene expression in colorectal cancer

Pytorch_all_l Benchmarks – OpenBenchmarking.org

AMD Ryzen 9 5900X 12-Core testing with a ASUS TUF GAMING B550M-PLUS (WI-FI) (1801 BIOS) and MSI NVIDIA GeForce RTX 3080 10GB on Ubuntu 22.04 via the Phoronix Test Suite. Compare your own system(s) to this result file with the Phoronix Test Suite by running the command: phoronix-test-suite benchmark 2312292-NE-PYTORCHAL51…

Continue Reading Pytorch_all_l Benchmarks – OpenBenchmarking.org

Trial for Opdualag in Metastatic Colorectal Cancer Ends Prematurely

The phase 3 RELATIVITY-123 trial was discontinued because it was unlikely for it to reach its goals. A phase 3 trial that evaluated treatment with Opdualag (nivolumab/relatlimab) for patients with metastatic microsatellite stable (MSS) colorectal cancer who have been previously treated will be discontinued, according to a news release from…

Continue Reading Trial for Opdualag in Metastatic Colorectal Cancer Ends Prematurely

Owkin and MSD to collaborate on cancer diagnostics

Artificial intelligence (AI) biotech firm Owkin has formed a collaboration with MSD, the tradename of Merck, to develop and commercialize AI-powered digital microsatellite instability high (MSI-H) pathology cancer diagnostics for EU markets. The financial terms of the agreement have not been disclosed. The collaboration seeks to develop a pre-screening procedure…

Continue Reading Owkin and MSD to collaborate on cancer diagnostics

BMS Ends Phase 3 Trial of Nivolumab and Relatlimab in CRC

Colorectal Cancer: © peterschreiber.media – stock.adobe.com Bristol Myers Squibb is ending the phase 3 RELATIVITY-123 trial (NCT05328908) investigating nivolumab (Opdivo) and relatlimab (Opdualag) in patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer (CRC) with disease progression following 1, but no more than 4 lines of therapy, due to…

Continue Reading BMS Ends Phase 3 Trial of Nivolumab and Relatlimab in CRC

Individual Disease Histology and Local Control Are Key Considerations in Endometrial Cancer Care

Systemic therapy and surgery have become mainstays in the treatment of patients with endometrial cancer, although further research is necessary to delineate the optimal use of radiation and later-line immunotherapy in this patient population, according to Hope Cottrill, MD. The phase 3 NRG-GY018 trial (NCT03914612) evaluated the efficacy and safety…

Continue Reading Individual Disease Histology and Local Control Are Key Considerations in Endometrial Cancer Care

A Treatment Option for Metastatic Colorectal Cancer Patients with BRAFV600E Mutation in Singapore | Taiwan News

Targeted therapy regimen, BRAFTOVI® (encorafenib) in combination with cetuximab, included on MOH Cancer Drug List, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer who have received prior systemic therapy. BRAFTOVI in combination with cetuximab has been included on MOH CDL, for patients with BRAFV600E-mutant metastatic colorectal cancer…

Continue Reading A Treatment Option for Metastatic Colorectal Cancer Patients with BRAFV600E Mutation in Singapore | Taiwan News

Expert Guidelines Detail Optimal Sequencing of Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer, Journal Club

Read the Full Video Transcript Rashid Sayyid: Hello everyone and thank you for joining us in this UroToday recording. I’m Rashid Sayyid, the Urologic Oncology Fellow at the University of Toronto, and along with Zach Klaassen, Associate Professor Program Director at Wellstar MCG Health, we’ll be discussing the recently amended…

Continue Reading Expert Guidelines Detail Optimal Sequencing of Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer, Journal Club

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

TOKYO, Dec 11, 2023 – (JCN Newswire) – Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced that the Phase 3 LEAP-001 trial evaluating LENVIMA®, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA®,…

Continue Reading Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

2023-12-08 | NYSE:MRK | Press Release

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, did not meet its dual primary endpoints of overall…

Continue Reading 2023-12-08 | NYSE:MRK | Press Release

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma -December 08, 2023 at 06:47 am EST

Merck and Eisai announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of patients with…

Continue Reading Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma -December 08, 2023 at 06:47 am EST

Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)

PRINCETON, N.J.–(BUSINESS WIRE)–   Bristol Myers Squibb Company Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary Endpoint Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -8HW trial evaluating…

Continue Reading Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)

CheckMate-8HW Meets Primary End Points With Nivolumab/Ipilimumab in mCRC

Colorectal Cancer: © peterschreiber.media – stock.adobe.com The combination of nivolumab (Opdivo) with ipilimumab (Yervoy) as a first-line treatment for patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) vs investigator’s choice of chemotherapy in the…

Continue Reading CheckMate-8HW Meets Primary End Points With Nivolumab/Ipilimumab in mCRC

Next Generation Sequencing Helps With Cancer Treatment Decisions

Singer and songwriter Sheryl Crow, 61, discovered she had early-stage breast cancer after undergoing a routine mammogram. For women diagnosed with breast cancer, it’s important to ask your doctor about next-generation sequencing, especially during these early critical stages of your journey. Next-generation sequencing (NGS) is a specific type of technology used…

Continue Reading Next Generation Sequencing Helps With Cancer Treatment Decisions

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic…

Application based on results from the Phase 3 CheckMate -901 trial showing significant survival improvement vs. standard-of-care gemcitabine plus cisplatin in cisplatin-eligible patients with untreated, unresectable or metastatic urothelial carcinoma If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the U.S. The…

Continue Reading U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic…

Serial Next Generation Sequencing and the Role of PARP Inhibitor Therapy in 2024

(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28th and December 1st, 2023, was host to a prostate cancer course. Dr. Alan Bryce provided an overview of the use and application of serial next generation sequencing (NGS) in the castrate-resistant prostate cancer disease…

Continue Reading Serial Next Generation Sequencing and the Role of PARP Inhibitor Therapy in 2024

Susceptibility of bovine to SARS-CoV-2 variants of concern: insights from ACE2, AXL, and NRP1 receptors | Virology Journal

WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. 2023/10/18. covid19.who.int/. Accessed 18 Oct 2023. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020;55:105955. doi.org/10.1016/j.ijantimicag.2020.105955. Article  CAS  PubMed  PubMed Central  Google Scholar …

Continue Reading Susceptibility of bovine to SARS-CoV-2 variants of concern: insights from ACE2, AXL, and NRP1 receptors | Virology Journal

Maintenance Selinexor Shows PFS in TP53 Wild-type Endometrial Cancer

Selinexor did not show a clinically meaningful improvement in the general study population. Maintenance selinexor (Xpovio) showed a significant progression-free survival (PFS) benefit compared with placebo in a subgroup of patients with TP53 wild-type advanced/recurrent endometrial cancer, according to findings from the phase 3 ENGOT-EN5/GOG-3055/SIENDO trial (NCT03555422).1,2 Data from the…

Continue Reading Maintenance Selinexor Shows PFS in TP53 Wild-type Endometrial Cancer

what is the background on genomic sequencing technologies

why genetics of neuromuscular disorders important? 4 answers what is the New Generation of Revolutionary Sequencing Technology Based on Semiconductor Chips 4 answers what is the purpose of fertilisation check in IVF 3 answers What are the limitations of challenge tests for genomic prediction? 4 answers What is the role…

Continue Reading what is the background on genomic sequencing technologies

Selinexor Maintenance Leads to PFS Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer

Maintenance therapy with selinexor (Xpovio) improved progression-free survival (PFS) compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer, regardless of microsatellite instability (MSI) status, according to long-term follow-up data from the phase 3 ENGOT-EN5/GOG-3055/SIENDO trial (NCT03555422)presented at the 2023 IGCS Annual Global Meeting.1 At a median…

Continue Reading Selinexor Maintenance Leads to PFS Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer

how to get ER, PR and HER2 data from TCGA BRCA

how to get ER, PR and HER2 data from TCGA BRCA 2 Hi I have dowloaded the BRCA data from TCGA using TCGABiolinks I have done this: BRCARnaseqSE <- GDCprepare(query.a, directory = “BRCA_all”) sample.info <- SummarizedExperiment::colData(BRCARnaseqSE) Now I want to get data on ER, PR and HER2 – positive, negative…

Continue Reading how to get ER, PR and HER2 data from TCGA BRCA

Tempus Announces Medicare Coverage for Tempus|xT Across Solid Tumor and Hematologic Malignancies

CHICAGO, November 15, 2023–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor, and the Molecular Diagnostics Services Program (MolDx) has approved coverage for Tempus|xT, Tempus’ 648-gene DNA sequencing panel, for use in solid tumor and hematologic malignancies, performed in Tempus’…

Continue Reading Tempus Announces Medicare Coverage for Tempus|xT Across Solid Tumor and Hematologic Malignancies

Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights

Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic and melanoma cancer patients, respectively Four-year follow-up…

Continue Reading Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights

The mystery of the ‘black box’ at the MacBook event. What is that object?

The mystery of the ‘black box’ at the MacBook event. What is that object? On October 30th, during the latter part of Apple’s new MacBook Pro unveiling event, a black machine box connected to the MacBook was briefly captured on camera. The presenter at the event was discussing the speed…

Continue Reading The mystery of the ‘black box’ at the MacBook event. What is that object?

Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting

NATICK, Mass., Nov. 8, 2023 /PRNewswire/ — Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City,…

Continue Reading Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting

GSK’s Jemperli combination shows promise in phase 3 endometrial cancer trial

GSK has announced positive results from a late-stage trial of its PD-1 inhibitor Jemperli (dostarlimab) plus chemotherapy in adults with primary advanced or recurrent endometrial cancer. The phase 3 RUBY trial has been evaluating Jemperli plus standard-of-care chemotherapy (carboplatin and paclitaxel), followed by Jemperli as a single agent, compared to…

Continue Reading GSK’s Jemperli combination shows promise in phase 3 endometrial cancer trial

T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

Hedrick, S. M., Cohen, D. I., Nielsen, E. A. & Davis, M. M. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 308, 149–153 (1984). Article  CAS  PubMed  Google Scholar  Yanagi, Y. et al. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains….

Continue Reading T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe, Business News

SHANGHAI, Oct. 25, 2023 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient in Europe has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company’s self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination with chemotherapy and concurrent radiotherapy in patients with limited-stage small cell lung…

Continue Reading First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe, Business News

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe

SHANGHAI, Oct. 25, 2023 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient in Europe has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company’s self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination with chemotherapy and concurrent radiotherapy in patients with limited-stage small cell lung…

Continue Reading First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe

Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Antibodies

Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma Details Category: Antibodies Published on Thursday, 19 October 2023 13:34 Hits: 279 Subcutaneous nivolumab demonstrates noninferior pharmacokinetics (co-primary endpoints) and objective response rate (key secondary endpoint) compared…

Continue Reading Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Antibodies

Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients

Paired tumor and normal DNA samples from 30 patients were subjected to WES at four ZPM laboratories with subsequent data analysis performed at five ZPM bioinformatic institutions (Fig. 1). DNA was originally derived from fresh-frozen samples that had been analyzed by WES within the multicenter MASTER (Molecularly Aided Stratification for…

Continue Reading Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients

PHF5A is a potential diagnostic, prognostic, and immunological biomarker in pan-cancer

PHF5A expression analysis Figure 1A demonstrated that PHF5A expression level was compared between tumor and corresponding normal tissues using TIMER2 tool. As compared to normal tissues, PHF5A expression was considerably elevated in Bladder urothelial carcinoma (BLCA), Breast invasive carcinoma (BRCA), Cholangiocarcinoma (CHOL), Colon adenocarcinoma (COAD), Esophageal carcinoma (ESCA), Head and neck…

Continue Reading PHF5A is a potential diagnostic, prognostic, and immunological biomarker in pan-cancer

Parallel Computing on Agate | The Minnesota Supercomputing Institute

Location & Details 575 Walter Library and online About This Event:  In this tutorial, we will give an overview of the Agate cluster resources, the newest high performance computing cluster at MSI. We will walk through examples that use SLURM job arrays, as well as the main two ways to…

Continue Reading Parallel Computing on Agate | The Minnesota Supercomputing Institute

Mixed infections in genotypic drug-resistant Mycobacterium tuberculosis

Global clinical results A total of 50,723 M. tuberculosis isolates with WGS and drug susceptibility test data from 64 countries were analysed, and encompassed all major lineages (L4 48.3%, L2 27.6%, L3 11.8%, L1 9.1%) (Table 1, Fig. 1B). Lineage 2.2.1 (Beijing strain-type) is the most prevalent in four of six…

Continue Reading Mixed infections in genotypic drug-resistant Mycobacterium tuberculosis

[The Potential of a Novel Therapeutic Strategy for Colorectal Cancer Targeting the cGAS-STING Pathway]

The cyclic GMP-AMP synthase(cGAS)-stimulator of interferon genes(STING)pathway is one of the important intracellular signaling pathways responsible for the recognition of exogenous DNA and subsequent induction of type Ⅰ interferon responses. Interestingly, in recent years, the importance of the cGAS-STING pathway in promoting anti-tumor immune responses has been highlighted. Decreased expression…

Continue Reading [The Potential of a Novel Therapeutic Strategy for Colorectal Cancer Targeting the cGAS-STING Pathway]

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology

Key Points Question  How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings  In this phase 3 randomized clinical trial of 674 patients with HCC, tislelizumab demonstrated overall survival noninferiority compared with sorafenib, with numerically…

Continue Reading Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology

RNA-Seq Analysis | University of Minnesota Online

This tutorial covers the process of handling bulk RNAseq data with command line tools. Attendees will learn the structure of a “standard” bulk RNAseq analysis workflow and the names of commonly used tools to process the data. We will cover the setup and use of a command line MSI-developed analytical…

Continue Reading RNA-Seq Analysis | University of Minnesota Online

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol-Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -77T trial met its primary endpoint of improved event-free survival (EFS) as assessed by Blinded Independent Central Review (BICR) in patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). In a prespecified interim analysis,…

Continue Reading Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo

Salani Reviews Options for a Patient With Metastatic Endometrial Cancer

Ritu Salani, MD, MBA Gynecologic Oncologist UCLA Health Los Angeles, CA CASE SUMMARY August 2021 A 64-year-old postmenopausal woman presented with abnormal uterine bleeding lasting 4 months. She noted that she underwent menopause at 55 years of age. She is a widow, has no children, and lives alone. Medical history:…

Continue Reading Salani Reviews Options for a Patient With Metastatic Endometrial Cancer

Efforts Are Underway to Refine Prognostic Value of ctDNA to Guide Adjuvant Therapy in CRC

Circulating tumor DNA(ctDNA) status at the time of postoperative minimal residual disease (MRD) is a prognostic factor of recurrence for patients with radically resected stage II to IV colorectal cancer (CRC). Standard management calls for adjuvant chemotherapy for all patients following surgical resection; however, investi- gators have sought to refine…

Continue Reading Efforts Are Underway to Refine Prognostic Value of ctDNA to Guide Adjuvant Therapy in CRC

ggplot2 – Plotting non-numerical data on R in the style of a heatmap

I have a dataframe from a csv file with metadata from cancer tumors (age, sex at birth, tumor location, treatment type, etc). I would like to plot this information like the following figure: enter image description here With the tumor.ID on the x-axis and each metadata category on the x-axis,…

Continue Reading ggplot2 – Plotting non-numerical data on R in the style of a heatmap

Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment

Patient characteristics In our analysis, we included patients with biliary tract cancer and available comprehensive molecular characterization data from five Austrian cancer centers. The data cut-off date was September 2022 (Fig. 1). Figure 1 Trial design: Flow chart depicting patient allocation. In total, the molecular profile of 159 patients with biliary…

Continue Reading Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment

Nokia (NOK), Google Cloud Team Up to Accelerate AI Development – September 18, 2023

Nokia Corporation (NOK Quick QuoteNOK – Free Report) recently unveiled AVA Data suite on Google Cloud, the cloud platform of Alphabet Inc. (GOOGL Quick QuoteGOOGL – Free Report) , to augment the development of software solutions with advanced AI-ML capabilities. The AVA Data suite is a comprehensive collection of readily…

Continue Reading Nokia (NOK), Google Cloud Team Up to Accelerate AI Development – September 18, 2023

Precision treatment of cholangiocarcinoma: current strategies and future directions

Cholangiocarcinoma is an aggressive malignant tumor originating from the biliary tract and can be divided into three subtypes based on anatomical location: intrahepatic cholangiocarcinoma, perihepatic cholangiocarcinoma, and distal cholangiocarcinoma [1]. Although progress has been made in the field of cholangiocarcinoma treatment in recent years, cholangiocarcinoma mortality remains high [2]. Although…

Continue Reading Precision treatment of cholangiocarcinoma: current strategies and future directions

Roche hiring Principal Scientist I Bioinformatics in Mississauga, Ontario, Canada

The PositionRoche Sequencing Solutions (RSS), a business within Roche Diagnostics, focused on developing a disruptive Next-Generation Sequencing (NGS) platform along with a portfolio of reagents, assays and informatics solutions for multiple disease areas. We are looking for a Principal Bioinformatics Scientist in the NGS Algorithms and Applications team to support…

Continue Reading Roche hiring Principal Scientist I Bioinformatics in Mississauga, Ontario, Canada

TCGAbiolinks MSI data

TCGAbiolinks MSI data 0 Hi! I am trying to use this code to access Microsatellita data: query <- GDCquery(project = “TCGA-COAD”, data.category = “Other”, legacy = TRUE, access = “open”, data.type = “Auxiliary test”, barcode = c(“TCGA-AD-A5EJ”,”TCGA-DM-A0X9″)) from TCGAbiolinks help documents, but I have this error message: “Error in checkDataCategoriesInput(project,…

Continue Reading TCGAbiolinks MSI data

Microbiology and Immunology Bioinformatics Analyst

Job Description About the Job The Research Informatics (RI) Bioinformatics group within the University of Minnesota Supercomputing Institute (MSI) is hiring a full-time Bioinformatics Analyst to support research for the Department of Microbiology and Immunology (MI) at the University of Minnesota. The analyst in this position will conduct cutting-edge bioinformatics…

Continue Reading Microbiology and Immunology Bioinformatics Analyst

Step-by-Step Guide to Setup Pytorch for Your GPU on Windows 10/11

In this competitive world of technology, Machine Learning and Artificial Intelligence technologies have emerged as a breakthrough for developing advanced AI applications like image recognition, natural language processing, speech translation, and more. However, developing such AI-powered applications would require massive amounts of computational power far beyond the capabilities of CPUs…

Continue Reading Step-by-Step Guide to Setup Pytorch for Your GPU on Windows 10/11

A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal Cancer

Background Effective treatment options are limited for patients (pts) with refractory metastatic colorectal cancer (mCRC). Fruquintinib (F), a highly selective, potent, oral tyrosine kinase inhibitor of VEGFR-1, -2, and -3, was approved in China in the 3L+ mCRC setting based on results from the FRESCO trial (NCT02314819). FRESCO-2 (NCT04322539) evaluated…

Continue Reading A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal Cancer

University of Minnesota hiring Bioinformatics Analyst in Greater Minneapolis-St. Paul Area

About the Job The Research Informatics (RI) Bioinformatics group within the University of Minnesota Supercomputing Institute (MSI) is hiring a full-time Bioinformatics Analyst to support research for the Department of Microbiology and Immunology (MI) at the University of Minnesota. The analyst in this position will conduct cutting-edge bioinformatics analyses in…

Continue Reading University of Minnesota hiring Bioinformatics Analyst in Greater Minneapolis-St. Paul Area

Merck (MRK) and Eisai Provide Update on Phase 3 LEAP-010 Trial of KEYTRUDA pus LENVIMA

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided an update on the Phase 3 LEAP-010 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, as a first-line treatment for patients…

Continue Reading Merck (MRK) and Eisai Provide Update on Phase 3 LEAP-010 Trial of KEYTRUDA pus LENVIMA

AMD Radeon 7900 XTX Achieves 890% Speedup In Generative AI With Stable Diffusion Optimization

NVIDIA is absolutely dominating the AI conversation right and for good measure – their GPUs perform out-of-the-box and are a top choice for professionals and businesses that want to dabble in consumer AI. But just this week, both Intel and AMD optimized their software stacks to get massive speedups in…

Continue Reading AMD Radeon 7900 XTX Achieves 890% Speedup In Generative AI With Stable Diffusion Optimization

Biliary Tract Cancers Clinical Practice Guidelines (NCCN, 2023)

Recent updates to the National Comprehensive Cancer Network (NCCN) guidelines for the evaluation and management of patients with biliary tract cancers (BTCs) (gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma) were published in July 2023 in the Journal of the NCCN (JNCCN).[1] Select recommendations for molecular testing and for systemic therapy…

Continue Reading Biliary Tract Cancers Clinical Practice Guidelines (NCCN, 2023)

Innovative research on schistosomiasis-associ | EurekAlert!

image: Genomic landscape of schistosomiasis-associated colorectal cancer. (A) Genetic characteristics of the SA-CRC. The number of mutations, the tumor mutation burden, the estimated MSI scores, and the predicted number of neo-epitopes of each sample were present. (B) Mutational landscape of recurrently mutated genes in SA-CRCs. Red arrow corresponds to the known…

Continue Reading Innovative research on schistosomiasis-associ | EurekAlert!

Unique Genetic Insights Revolutionize SA-CRC Treatment

In a study published in the journal Genes & Diseases, researchers from Naval Medical University and Soochow University conducted an in-depth investigation into the genomic landscape of schistosomiasis-associated colorectal cancer (SA-CRC). By utilizing whole exome sequencing on tumor tissues and their non-tumor counterparts obtained from thirty SA-CRC patients diagnosed at…

Continue Reading Unique Genetic Insights Revolutionize SA-CRC Treatment

Principal Scientist II Bioinformatics – Hiring Now at F. Hoffmann-La Roche Ltd in Mississauga, ON

We are searching for a persistent Principal Scientist II Bioinformatics to join our energetic team at F. Hoffmann-La Roche Ltd in Mississauga, ON.Growing your career as a Full Time Principal Scientist II Bioinformatics is an incredible opportunity to develop key skills.If you are strong in leadership, critical thinking and have…

Continue Reading Principal Scientist II Bioinformatics – Hiring Now at F. Hoffmann-La Roche Ltd in Mississauga, ON

Selecting Therapy for dMMR/MSI-H Endometrial Cancer After Chemotherapy

Jubilee Brown, MD Professor of Gynecologic Oncology Atrium Health Levine Cancer Institute Charlotte, NC CASE SUMMARY In August 2021, a 64-year-old postmenopausal woman presented with abnormal uterine bleeding lasting 4 months. ​She underwent menopause at 55 years of age. She is a widow, has no children, and lives alone​. She had…

Continue Reading Selecting Therapy for dMMR/MSI-H Endometrial Cancer After Chemotherapy

Detecting gene fusions offers new avenues for advanced cancer management

In a recent article published in the Biologics Journal, researchers examined de-identified clinical data to identify gene fusions by next-generation deoxy- and ribonucleic acids (DNA and RNA) sequencing to understand their relationship with observed pathologies in a diverse population of cancer patients. Study: Precision Medicine in a Community Cancer Center: Pan-Cancer DNA/RNA…

Continue Reading Detecting gene fusions offers new avenues for advanced cancer management

Down-regulation of stimulator of interferon genes (STING) expression and CD8+ T-cell infiltration depending on HER2 heterogeneity in HER2-positive gastric cancer

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635–48. Article  CAS  PubMed  Google Scholar  Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. Article  PubMed  Google Scholar  Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat…

Continue Reading Down-regulation of stimulator of interferon genes (STING) expression and CD8+ T-cell infiltration depending on HER2 heterogeneity in HER2-positive gastric cancer

Bioinformatics Analyst Job in Minnesota

The Research Informatics (RI) Bioinformatics group within the University of Minnesota Supercomputing Institute (MSI) is hiring a full-time Bioinformatics Analyst to support basic biomedical and applied clinical genetic research for the Department of Laboratory Medicine and Pathology (LM&P) at the University of Minnesota. The analyst in this position will…

Continue Reading Bioinformatics Analyst Job in Minnesota

‘Unprecedented’ Results Support Dostarlimab Approval in Endometrial Cancer

In an interview with CancerNetwork®, Brian Slomovitz, MD, MS, FACOG, spoke about “unprecedented” findings from the phase 3 RUBY trial (NCT03981796) that supported the FDA approval of dostarlimab (Jemperli) plus chemotherapy as a treatment for patients with primary advanced or recurrent mismatch repair deficient (dMMR) or microsatellite instability–high (MSI-H) endometrial…

Continue Reading ‘Unprecedented’ Results Support Dostarlimab Approval in Endometrial Cancer

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy U.S. Food and Drug Administration approval represents a potential significant…

Continue Reading AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Pacbio job searching

Chula Vista scolds Republic Service for lingering strike, may sever ties with waste hauler. Public Safety. County Board of Supervisors approves ordinance to outlaw ghost guns. San Diego City Council approves school rebuild plan. New proposal would transform much of northeast Mission Bay into marshland. Two people shot, deputies searching…

Continue Reading Pacbio job searching

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer | Antibodies

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer Details Category: Antibodies Published on Friday, 28 July 2023 17:17 Hits: 194 KEYTRUDA® (pembrolizumab) plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus…

Continue Reading Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer | Antibodies

Torch.cuda.is_available() is False – CUDA:12.2 – rtx 4070

TTTest July 28, 2023, 12:02pm 1 Machine learning newbie here, stuck on the first step of learning PyTorch of installing CUDA. I’ve been trying to get CUDA working on my system for the past day to no avail. I’ve created multiple environments then tried installing pytorch using the below config…

Continue Reading Torch.cuda.is_available() is False – CUDA:12.2 – rtx 4070

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

July 28, 2023 6:45 am ET KEYTRUDA® (pembrolizumab) plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus chemotherapy KEYNOTE-756 is the first positive Phase 3 study with an immunotherapy regimen to demonstrate a statistically significant improvement in pCR rate in the neoadjuvant setting for this patient…

Continue Reading Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

XPORT-EC-042 Studies Selinexor Maintenance in TP53WT Endometrial Cancer

About the Phase 3 XPORT-EC-042 Study Trial Name: A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma ClinicalTrials.gov Identifier: NCT05611931 Sponsor: Karyopharm Therapeutics Inc. Recruitment Contact: Karyopharm Medical Information, (888) 209-9326, clinicaltrials@karyopharm.com Completion…

Continue Reading XPORT-EC-042 Studies Selinexor Maintenance in TP53WT Endometrial Cancer

A systems biology approach to pathogenesis of gastric cancer: gene network modeling and pathway analysis | BMC Gastroenterology

In recent years, different investigations in the area of multi-center genomics research from gene to systems level and next-generation sequencing, clarified the various mechanisms specifically involved in the tumor progression [29]. This study used bioinformatics analysis to further investigate the genes involved in GC pathogenesis. In addition, the current study…

Continue Reading A systems biology approach to pathogenesis of gastric cancer: gene network modeling and pathway analysis | BMC Gastroenterology

Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer | Antibodies

Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer Details Category: Antibodies Published on Wednesday, 19 July 2023 18:10 Hits: 115 KEYTRUDA® (pembrolizumab) plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus…

Continue Reading Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer | Antibodies

Principal Bioinformatics Engineer Job Opening in Waltham, MA at BIO-TECHNE

Job Details Level:    Experienced Job Location:    Waltham MA – Waltham, MA Position Type:    Full Time Education Level:    Graduate Degree Salary Range:    Undisclosed Travel Percentage:    Up to 10% Job Shift:    Day Job Category:    Research Description Principal Bioinformatics Engineer   The Opportunity Exosome Diagnostics, a Bio-Techne brand (NASDAQ: TECH), is a global…

Continue Reading Principal Bioinformatics Engineer Job Opening in Waltham, MA at BIO-TECHNE

Exploring Co-Mutation Patterns Linked to Actionable Drivers in iCCA

The following is a summary of the “Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma,” published in the March 2023 issue of Hepatology by Kendre, et al. For precision oncology in gastrointestinal malignancies, intrahepatic cholangiocarcinoma (iCCA) has emerged as a “role model” in recent years. However, its genetic…

Continue Reading Exploring Co-Mutation Patterns Linked to Actionable Drivers in iCCA

A prognostic four-gene signature and a therapeutic strategy for hepatocellular carcinoma: Construction and analysis of a circRNA-mediated competing endogenous RNA network

Background: Hepatocellular carcinoma (HCC) has a poor long-term prognosis. The competition of circular RNAs (circRNAs) with endogenous RNA is a novel tool for predicting HCC prognosis. Based on the alterations of circRNA regulatory networks, the analysis of gene modules related to HCC is feasible. Methods: Multiple expression datasets and RNA…

Continue Reading A prognostic four-gene signature and a therapeutic strategy for hepatocellular carcinoma: Construction and analysis of a circRNA-mediated competing endogenous RNA network

Create a compute instance – Azure Machine Learning

Article 07/06/2023 2 contributors Feedback In this article APPLIES TO: Azure CLI ml extension v2 (current) Python SDK azure-ai-ml v2 (current) Learn how to create a compute instance in your Azure Machine…

Continue Reading Create a compute instance – Azure Machine Learning

Principal Scientist I Bioinformatics job with F. Hoffmann-La Roche AG

The Position Roche Sequencing Solutions (RSS), a business within Roche Diagnostics, focused on developing a disruptive Next-Generation Sequencing (NGS) platform along with a portfolio of reagents, assays and informatics solutions for multiple disease areas. We are looking for a Principal Bioinformatics Scientist in the NGS Algorithms and Applications team to…

Continue Reading Principal Scientist I Bioinformatics job with F. Hoffmann-La Roche AG

Senior Principal Bioinformatics Scientist, NGS Algorithms job with F. Hoffmann-La Roche AG

The Position Roche Sequencing Solutions (RSS), a business within Roche Diagnostics, focused on developing a disruptive Next-Generation Sequencing (NGS) platform along with a portfolio of reagents, assays and informatics solutions for multiple disease areas. We are looking for a Principal Bioinformatics Scientist in the NGS Algorithms and Applications team to…

Continue Reading Senior Principal Bioinformatics Scientist, NGS Algorithms job with F. Hoffmann-La Roche AG

Mismatch Repair Deficiency Shapes Tumor-Agnostic Use of Immunotherapy

Cancer immunotherapies have transformed the treatment landscape of many tumor types by stimulating the body’s mechanisms of targeting cancer cells. The efficacy of immune checkpoint inhibitors (ICIs) can vary widely between different tumor types based on immunogenicity and other factors—even patients with the same disease may respond very differently to…

Continue Reading Mismatch Repair Deficiency Shapes Tumor-Agnostic Use of Immunotherapy

Integration of bulk RNA sequencing data and single-cell RNA sequencing analysis on the heterogeneity in patients with colorectal cancer

Bao X, Shi R, Zhao T, Wang Y, Anastasov N, Rosemann M et al (2021) Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC. Cancer Immunol Immunother 70(1):189–202 Article  CAS  PubMed  Google Scholar  Becht E, McInnes L, Healy J,…

Continue Reading Integration of bulk RNA sequencing data and single-cell RNA sequencing analysis on the heterogeneity in patients with colorectal cancer

Recent FDA Actions: June 2023

FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma The FDA has granted accelerated approval to enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.1 The regulatory decision was supported by data from the…

Continue Reading Recent FDA Actions: June 2023

Physicians Discuss the Addition of Cabizatxel to Treatment in mCRPC

CASE SUMMARY A 75-year-old man presented with intermittent left hip pain and his physical exam was unremarkable expect for a prostate nodule on a rectal exam. The patient had an ECOG performance score of 1 and a prostate-specific antigen (PSA) of 16.2 ng/mL with a transrectal ultrasound scan (TRUS) and…

Continue Reading Physicians Discuss the Addition of Cabizatxel to Treatment in mCRPC

Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

RAHWAY, N.J., June 20, 2023–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the Phase 3 KEYNOTE-585 trial, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as neoadjuvant treatment, followed by adjuvant treatment with KEYTRUDA plus chemotherapy, then KEYTRUDA…

Continue Reading Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Six molecular diagnostics companies to watch

You may have heard of the enzyme-linked immunosorbent assay, more commonly known as the ELISA test, which is used to measure molecules like antibodies, antigens and proteins in biological samples. Used to diagnose infections caused by human immunodeficiency viruses (HIV) as well as to detect the pregnancy hormone human chorionic…

Continue Reading Six molecular diagnostics companies to watch

Senior Principal Scientist Bioinformatics job with F. Hoffmann-La Roche AG

The Position Roche Sequencing Solutions (RSS), a business within Roche Diagnostics, focused on developing a disruptive Next-Generation Sequencing (NGS) platform along with a portfolio of reagents, assays and informatics solutions for multiple disease areas. We are looking for a Principal Bioinformatics Scientist in the NGS Algorithms and Applications team to…

Continue Reading Senior Principal Scientist Bioinformatics job with F. Hoffmann-La Roche AG

FDA Updates for the Week of June 5, 2023

FDA Approves Novel Cyclosporine for Dye Eye Disease The FDA has approved Novaliq’s Vevye (cyclosporine) 0.1% to treat patients with dry eye disease. Vevye (which had development name CyclASol) is a water-free, preservative-free solution based on EyeSol technology. Cyclosporine is not water-soluble, but the EyeSol excipient perfluorobutylpentane allows for improved bioavailability…

Continue Reading FDA Updates for the Week of June 5, 2023

Dostarlimab Under Review for Primary Advanced or Recurrent Endometrial Cancer

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application for dostarlimab in combination with chemotherapy for the treatment of adults with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)-blocking antibody. The sBLA was supported by…

Continue Reading Dostarlimab Under Review for Primary Advanced or Recurrent Endometrial Cancer

Principal Scientist I Bioinformatics Job Opening in Santa Clara, CA at Roche Holdings Inc.

The Position Roche Sequencing Solutions (RSS), a business within Roche Diagnostics, focused on developing a disruptive Next-Generation Sequencing (NGS) platform along with a portfolio of reagents, assays and informatics solutions for multiple disease areas. We are looking for a Principal Bioinformatics Scientist in the NGS Algorithms and Applications team to…

Continue Reading Principal Scientist I Bioinformatics Job Opening in Santa Clara, CA at Roche Holdings Inc.

Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab)

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942 study, will be presented at the 2023 American Society of Clinical…

Continue Reading Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab)

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Patients treated with dual immunotherapy-based combination demonstrate sustained clinical benefits after four years vs. chemotherapy alone, with magnitude of benefit more pronounced amongst patient subgroups with high unmet needs Late-breaking data to be presented during the 2023 American Society of Clinical Oncology Annual Meeting PRINCETON, N.J., June 04, 2023–(BUSINESS WIRE)–Bristol…

Continue Reading Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Dostalimab Plus Chemotherapy Shows Similar HRQOL Results in Patients with Endometrial Cancer

Health-related quality-of-life (HRQOL) outcomes from the phase 3 ENGOT-EN6/GOG3031/RUBY trial (NCT03981796) shows patients with primary advanced or recurrent endometrial cancer were not adversely affected by the combination of dostarlimab-gxly (Jemperli) and carboplatin/paclitaxel (CP) more so than chemotherapy alone, according to data presented at the 2023 ASCO Annual Meeting.1 Patient reported…

Continue Reading Dostalimab Plus Chemotherapy Shows Similar HRQOL Results in Patients with Endometrial Cancer

Dostarlimab Maintains HRQOL in 3-Year Follow-Up Of Patients With Early Endometrial Cancer

An analysis of patient-reported outcomes (PROs) from the phase 3 ENGOT-EN6/GOG3031/RUBY trial (NCT03981796) suggest that dostarlimab-gxly (Jemperli) does not negatively affect health-related quality-of-life (HRQOL) outcomes when used in combination with carboplatin/paclitaxel (CP) in patients with primary advanced or recurrent endometrial cancer. Findings were presented during the 2023 American Society of…

Continue Reading Dostarlimab Maintains HRQOL in 3-Year Follow-Up Of Patients With Early Endometrial Cancer

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer | News

PRINCETON, N.J.–(BUSINESS WIRE)–Jun 4, 2023– Bristol Myers Squibb (NYSE: BMY) today announced four-year follow-up results from the Phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy compared to four cycles of chemotherapy alone in previously untreated patients with…

Continue Reading Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer | News

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer | Antibodies

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer Details Category: Antibodies Published on Sunday, 04 June 2023 15:16 Hits: 87 Patients treated with dual immunotherapy-based combination demonstrate…

Continue Reading Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer | Antibodies

Labcorp Introduces Groundbreaking Liquid Biopsy Test for Advanced Solid Tumors

Labcorp has recently made a groundbreaking announcement that its new liquid biopsy test, Plasma Focus, is now available for patients who are suffering from advanced or metastatic solid tumors. The test is a laboratory-developed test (LDT) that utilizes Next Generation Sequencing-based technology to detect genomic sequence mutations in 33 genes…

Continue Reading Labcorp Introduces Groundbreaking Liquid Biopsy Test for Advanced Solid Tumors

Multiple Factors at Play in the Rise of Early-Onset Colorectal Cancer

My colon cancer patients are getting younger. The diagnoses are happening just as some of these individuals are embarking on their plans for life, while others are in the crucial midst of parenthood. Given this, the tragedy of their cancers feels exponentially greater. This youthful trend in my clinic is…

Continue Reading Multiple Factors at Play in the Rise of Early-Onset Colorectal Cancer

GeForce RTX 4060 Family Is Here: NVIDIA’s Revolutionary Ada Lovelace Architecture Comes to Core Gamers Everywhere, Starting at $299

Superpowered by AI, Newest GPUs Provide 2x the Horsepower of Latest Gaming Consoles NVIDIA today announced the GeForce RTX™ 4060 family of GPUs, with two graphics cards that deliver all the advancements of the NVIDIA® Ada Lovelace architecture — including DLSS 3 neural rendering and third-generation ray-tracing technologies at high…

Continue Reading GeForce RTX 4060 Family Is Here: NVIDIA’s Revolutionary Ada Lovelace Architecture Comes to Core Gamers Everywhere, Starting at $299

Understanding Lynch Syndrome and Associated Cancer Risk: Identification

In this third episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, of Columbia University Herbert Irving Comprehensive Cancer Center, discusses testing guidance for identifying Lynch syndrome. Universal testing with MSI or immunohistochemistry [IHC] in all newly diagnosed colorectal cancer [CRC] is a firm guideline, and…

Continue Reading Understanding Lynch Syndrome and Associated Cancer Risk: Identification

Letter for the article Diagnosis of Acute Q Fever in a Patient by Usin

Center for Biomedical Research, Health Research Organization, National Research and Innovation Agency (BRIN), Cibinong, West Java, Indonesia Correspondence: Frans Dany, Biomedical Research Center, Health Research Organization, Genomic Building, Cibinong Science Center, Jl. Raya Bogor No. 490, Cibinong, 16911, West Java, Indonesia, Email [email protected]; [email protected] Dear editor We are very interested…

Continue Reading Letter for the article Diagnosis of Acute Q Fever in a Patient by Usin

Principal scientist bioinformatics – Urgent Role at Roche in Washington DC

We are looking to hire a resourceful Principal scientist bioinformatics to join our incredible team at Roche in Washington DC.Growing your career as a Full Time Principal scientist bioinformatics is an incredible opportunity to develop excellent skills.If you are strong in presentation, adaptability and have the right mindset for the…

Continue Reading Principal scientist bioinformatics – Urgent Role at Roche in Washington DC

Tempus granted FDA premarket approval for colorectal cancer CDx

Tempus on Monday announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) for its xT CDx sequencing test as a companion diagnostic. xT CDx is a 648-gene next-generation sequencing test (NGS) for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for…

Continue Reading Tempus granted FDA premarket approval for colorectal cancer CDx

Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device

xT CDx is the company’s first Premarket Approval from the FDA CHICAGO, May 01, 2023–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its companion diagnostic test, xT CDx….

Continue Reading Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device

5700U laptop ROCm for pytorch or tensorflow

Hello everyone, I’m new to the community This is my first post, I have a problem on my laptop I have a beautiful laptop which is msi Morden 15 A5M with 5700U and its own iGPU There’s no other gpus, and I got two DDR4 3200 16G rams the system…

Continue Reading 5700U laptop ROCm for pytorch or tensorflow